Glucose 5% Basi

Glucose 5% Basi is an intravenous solution containing 5 % w/v glucose as the active ingredient. It is supplied as a sterile, isotonic carbohydrate solution intended for parenteral administration. The product is classified as a carbohydrate solution and is marketed in the European Union. It is prescribed by healthcare professionals for use in clinical settings where rapid glucose delivery or fluid replacement is required and electrolyte balance.

Glucose 5% Basi is used in several clinical situations where a rapid source of carbohydrate or fluid replacement is needed.

- Treatment of acute hypoglycemia in patients unable to take oral glucose. - Component of parenteral nutrition regimens to provide caloric support. - Fluid and electrolyte replacement during surgery or trauma. - Dilution medium for intravenous drug admixtures. - Maintenance of blood glucose levels during prolonged fasting. - Support for patients with metabolic disorders requiring controlled glucose infusion.

Glucose 5% Basi may be associated with a range of adverse reactions, most of which are mild and transient.

Common: - Mild hyperglycemia when administered in excess. - Local irritation or pain at the infusion site. - Nausea or vomiting related to rapid glucose infusion. - Electrolyte shifts, particularly decreased serum potassium. - Transient headache due to rapid osmotic changes. - Mild metabolic acidosis in patients with impaired renal function.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Fluid overload causing pulmonary edema. - Allergic reactions such as urticaria or anaphylaxis. - Hyperosmolar hyperglycemic state in susceptible patients. - Hypoglycemia if glucose infusion is abruptly discontinued after prolonged use. - Severe electrolyte disturbances such as hypernatremia or hypocalcemia.

When prescribing Glucose 5% Basi, clinicians should consider several precautionary measures to ensure safe administration and minimize complications.

- Assess baseline blood glucose levels and continue periodic monitoring during the infusion to avoid both hyperglycemia and hypoglycemia. - Monitor cumulative fluid input and output, particularly in patients with congestive heart failure or impaired renal function, to prevent fluid overload. - Adjust the infusion rate based on the patient’s electrolyte status, especially potassium and sodium levels, to reduce the risk of shifts. - Employ strict aseptic technique when accessing the intravenous line to minimize the risk of catheter-associated bloodstream infections. - Avoid rapid bolus administration unless clinically indicated, as sudden glucose spikes can precipitate metabolic disturbances. - Confirm compatibility with other intravenous drugs before co‑administration, as incompatibility may cause precipitation or loss of efficacy. - Evaluate pregnancy status; current safety information is limited, so use only when the potential benefit justifies the potential risk.

Glucose 5% Basi can interact with other medications or clinical conditions, influencing its safety and effectiveness.

Avoid: - Co‑administration with insulin infusions without appropriate dose adjustments, which may cause severe hypoglycemia. - Simultaneous infusion of potassium chloride solutions, as rapid glucose delivery can increase serum potassium and precipitate arrhythmias.

Use with caution: - Concurrent use of diuretics that affect electrolyte balance; monitor potassium and sodium levels closely. - Administration with beta‑adrenergic agonists, which may enhance glycogenolysis and alter glucose requirements. - Use in patients receiving total parenteral nutrition containing other carbohydrate sources; adjust total glucose load to prevent hyperglycemia.